Sobi® (STO: SOBI), today announced a research collaboration involving a new Phase 2a clinical trial for Gamifant® (emapalumab) for the potential treatment of interferon-gamma (IFNγ)-driven sepsis (IDS ...

Sobi® (STO: SOBI), today announced a research collaboration involving a new Phase 2a clinical trial for Gamifant® (emapalumab) for the potential treatment of interferon-gamma (IFNγ)-driven sepsis (IDS ...

Sobi announces a new research collaboration on the development of Gamifant in sepsis, which is to be presented at the ISICEM congress: Stockholm Thursday, March 20, 2025, 12:00 Hr ...

The EMBRACE Phase 2a study will adopt a precision immunotherapy approach for the treatment of sepsis driven by the IDS ...

“Exciting” data were presented on emapalumab in the treatment of refractory macrophage activation syndrome (MAS) in patients with sJIA/Still disease. And the FDA approved three new drugs for JIA.

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStoptm for the treatment of acid reflux, a treatment field ...

HTX Research, the research arm of HTX Group, has released an in-depth report titled, "dTAO and the Evolution of Bittensor: Reshaping Decentralized AI with Market-Driven Incentives.". The evolution of ...

The table below is a review of notable updates that occurred in February 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

The Partial Heart Transplant Because Kids Grow, Valves Don’t Partial heart transplants provide a range of lifesaving options for children with complex congenital heart conditions, and can lead ...